Eiger BioPharmaceuticals to Participate in Two Upcoming Investor Conferences in February
PALO ALTO, Calif. – February 6, 2018 – Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today that David Cory, President and CEO of Eiger, will present a corporate overview and business update at two upcoming conferences in February.
- 2018 BIO CEO & Investor Conference, February 12, 2018 at 3:00 pm ET at the New York Marriott Marquis in New York City. Eiger will host one-on-one meetings.
- BTIG 5th Annual Healthcare Conference, February 26-28, 2018 in Snowbird, UT. Eiger will host one-on-one meetings.
A live webcast of the BIO CEO presentation will be available on the Eiger BioPharmaceuticals website at www.eigerbio.com under the “Investors” tab. A replay of the webcast will be available approximately one hour following the completion of the live event.
Eiger is a clinical-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for orphan diseases. We are committed to translational innovation and the development of well-characterized drugs acting on newly identified or novel targets. Our mission is to systematically reduce the time and cost of the drug development process to more rapidly deliver important medicines to patients with orphan diseases. For additional information about Eiger and its clinical programs, please visit www.eigerbio.com.
SOURCE Eiger BioPharmaceuticals, Inc.
Investors: Ingrid Choong, PhD